UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000049
Receipt number R000000090
Scientific Title A phase I/II study of transarterial chemoembolization with cisplatin for hepatocellular carcinoma (JIVROSG-0401)
Date of disclosure of the study information 2005/08/07
Last modified on 2012/09/21 13:23:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase I/II study of transarterial chemoembolization with cisplatin for hepatocellular carcinoma (JIVROSG-0401)

Acronym

Transarterial chemoembolization with cisplatin for hepatocellular carcinoma(JIVROSG-0401)

Scientific Title

A phase I/II study of transarterial chemoembolization with cisplatin for hepatocellular carcinoma (JIVROSG-0401)

Scientific Title:Acronym

Transarterial chemoembolization with cisplatin for hepatocellular carcinoma(JIVROSG-0401)

Region

Japan


Condition

Condition

Unresectable hypervascular hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine Hematology and clinical oncology Hepato-biliary-pancreatic surgery
Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the dose limiting toxicity (DLT) and the recommended dose (RD) of cisplatin on hepatic arterial chemoembolization for unresectable hypervascular hepatocellular carcinoma, and to evaluate safety and tumor response with this therapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Adverse events

Key secondary outcomes

Response rate of liver tumor and overall response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Patients undergo transarterial chemoembolization comprising intra-arterial infusion of cisplatin over 20-40 minutes followed by embolization with gelatin sponge particle until elimination of tumor stain is observed on proper hepatic arteriogram.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Histologically or clinically confirmed hepatocellular carcinoma.
2) No definitive extra-hepatic lesions and no indication for hepatic resection.
3) Measurable and hypervascular hepatocellular carcinoma on contrast-enhanced CT.
4) Multiple lesion in both lobes of the liver.
5) No tumor thrombus in main or 1st branch of the portal vein.
6) No influence of previous treatments.
7) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
8) Child-Pugh score of A or B.
9) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions.
10) Ages 20 years and above, under 75 years.
11) Expected survival more than 8 weeks.
12) Written informed consent.

Key exclusion criteria

1) Prior chemotherapy with cisplatin for HCC.
2) Suspicious of extra-hepatic arterial blood supply to lesions on contrast-enhanced CT.
3) Extra-hepatic arterial blood supply to lesions on prior angiography.
4) Surgical reconstruction or endoscopic treatment involving biliary system.
5) Lymphnode metastasis or distant metastasis.
6) Other uncontrolled severe illness.
7) Active infectious disease except viral hepatitis.
8) Active other malignancies.
9) Allergic reaction to iodine contrast material, platinum containing agent, or gelatin containing agent.
10) Pregnant or nursing.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Keigo Osuga

Organization

Osaka University Graduate School of Medicine

Division name

Department of Radiology

Zip code


Address

2-2, Yamadaoka, Suita, Osaka 565-0871, Japan

TEL

06-6879-3434

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yasuaki Arai

Organization

JIVROSG, Coordinating Office

Division name

Division of Diagnostic Radiology, National Cancer Center Hospital

Zip code


Address

5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan

TEL

03-3542-2511

Homepage URL

http://jivrosg.umin.jp/

Email

jivrosgoffice@ml.res.ncc.go.jp


Sponsor or person

Institute

Japan Interventional Radiology in Oncology Study Group (JIVROSG)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 08 Month 07 Day


Related information

URL releasing protocol

http://jivrosg.umin.jp/

Publication of results

Unpublished


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/22922041

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2005 Year 07 Month 18 Day

Date of IRB


Anticipated trial start date

2005 Year 10 Month 01 Day

Last follow-up date

2009 Year 06 Month 01 Day

Date of closure to data entry

2010 Year 01 Month 01 Day

Date trial data considered complete

2010 Year 01 Month 01 Day

Date analysis concluded

2010 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 08 Month 07 Day

Last modified on

2012 Year 09 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000090


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name